The H.C Wainwright Annual Global Conference is a major event and could be a positive one for CYDY.
I am nor normally overly optimistic (or pessimistic) about events (any) and more so after being long since 2018 with all the ups and downs along the way.
The conference has company presentations, One-on-One meetings with investors (Institutional, Hedge funds and Venture capital).
But, more importantly biotech analysts and the media show in force.
What will be a good outcome from our presence ??, again, not being overly optimistic an initiating coverage by analyst(s) with a good target price will greatly help us at this stage.
H.C. Wainwright is highly respected in the industry, as a recent example (6/17/25), another biotech company (GALT) was hovering at around $1.35 when Wainwright assumed coverage with a buy rating at a good target price, the stock has been in a rise ever since without any "medical" news (yesterday close $4.42).
So, several events affecting us can take place in the conference, in my opinion the most positive one is exposure to the "right" people, but let's don't forget the power of analyst's recommendations (coverage) whose audience is very broad and have the potential to affect the SP in a positive fashion. The investor's world "listens" to them.
One way or another, our presence there is positive. Let's hope there are actual (factual) outcomes.
I am nor normally overly optimistic (or pessimistic) about events (any) and more so after being long since 2018 with all the ups and downs along the way.
The conference has company presentations, One-on-One meetings with investors (Institutional, Hedge funds and Venture capital).
But, more importantly biotech analysts and the media show in force.
What will be a good outcome from our presence ??, again, not being overly optimistic an initiating coverage by analyst(s) with a good target price will greatly help us at this stage.
H.C. Wainwright is highly respected in the industry, as a recent example (6/17/25), another biotech company (GALT) was hovering at around $1.35 when Wainwright assumed coverage with a buy rating at a good target price, the stock has been in a rise ever since without any "medical" news (yesterday close $4.42).
So, several events affecting us can take place in the conference, in my opinion the most positive one is exposure to the "right" people, but let's don't forget the power of analyst's recommendations (coverage) whose audience is very broad and have the potential to affect the SP in a positive fashion. The investor's world "listens" to them.
One way or another, our presence there is positive. Let's hope there are actual (factual) outcomes.
31
